Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

BACKGROUND: We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV), TAF/FTC/elvitegravir/cobi (TAF/FTC/EVG/cobi) and ABC/lamivudine/dolutegravir (ABC/3TC/DTG)] in...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Infect Dis
Glavni autori: Giacomelli, Andrea, Conti, Federico, Pezzati, Laura, Oreni, Letizia, Ridolfo, Anna Lisa, Morena, Valentina, Bonazzetti, Cecilia, Pagani, Gabriele, Formenti, Tiziana, Galli, Massimo, Rusconi, Stefano
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8220746/
https://ncbi.nlm.nih.gov/pubmed/34157984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-021-06304-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items